22nd Century Group Inc. (XXII)
XXII trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1347858/000110465926034814/0001104659-26-034814-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | XXII on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001347858 |
| SEC industry code | Cigarettes |
| Incorporated in | FL |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $17.6M |
| Net income | -$5.1M |
| Operating income | -$11.6M |
| Net margin | -28.7% |
| Operating margin | -65.8% |
| Revenue growth | -27.9% |
| Cash | $7.1M |
| Total assets | $27.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Given the Company's projected operating requirements and its existing cash and cash equivalents, there is substantial doubt about the Company's ability to continue as a going concern through one year following the date that the Condensed Consolidated Financial Statements are issued." | 10-Q 2026-08-14 |
| Cash and burn | $6.1M cash; operating cash flow -$2.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-08-14 |
| Reverse splits, 3 years | 6; latest 1-for-58 on 2026-11-05 | Source 2026-11-05 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 6 424B5 takedowns, 3 at the market | Latest 2026-04-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | WithumSmith+Brown, PC, Buffalo, New York, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-08-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $2.9M | -$3.3M | -$4.0M | $6.1M | $1.1M | $14.5M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $4.1M | -$3.3M | -$3.1M | $9.5M | $588K | $15.7M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $3.5M | -$2.8M | $2.7M | $7.1M | $708K | $17.6M | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | $4.0M | $5.5M | -$4.0M | $4.8M | No debt tags | $18.1M | 10-Q 2025-11-04 |
| Q2 2025 2025-06-30 | $4.1M | -$3.4M | -$3.5M | $3.1M | $3.2M | $20.0M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $6.0M | -$4.3M | -$3.0M | $1.1M | $3.9M | $23.9M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $4.0M | -$4.6M | -$4.4M | $4.4M | $6.7M | $24.4M | 10-K 2026-03-26 |
| Q3 2024 2024-09-30 | $5.9M | -$3.8M | -$3.0M | $5.3M | $7.0M | $27.7M | 10-Q 2024-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-28 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-06-23 |
Source: SEC EDGAR submissions feed, 922 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -50.3% |
| 1 month | -98.0% |
| 3 months | -99.7% |
| Year to date | -100.0% |
| 1 year | -100.0% |
| From 52-week high | -100.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMCC | IM Cannabis Corp. Common Shares | $0.4950 | -12.76% | $913K |
| AKAN | Akanda Corp. Common Shares | $2.21 | +62.50% | $5.3M |
| NAII | Natural Alternatives International Inc. | $0.9700 | +0.35% | $6.1M |
| MTEX | Mannatech Incorporated | $3.76 | -40.32% | $7.3M |
| BON | Bon Natural Life Limited | $1.09 | -0.91% | $8.9M |
| BTMD | Biote Corp. | $0.9603 | -9.83% | $34.5M |
| FTLF | FitLife Brands Inc. | $6.83 | -19.46% | $64.1M |
| ISPR | Ispire Technology Inc. | $1.52 | -10.06% | $87.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier